U.S. FDA flags Aurobindo arm’s Hyderabad plant
The U.S. Food and Drug Administration issued an observation to AuroPeptides, Aurobindo Pharma's subsidiary, after a routine inspection of its Hyderabad facility from August 17 to 21. The observation concerns facility and equipment maintenance, not data integrity or GMP compliance. Aurobindo has already initiated corrective actions during the inspection process.